Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
about
Expression of topoisomerase IIIalpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibodyA phase I and pharmacokinetic study of intraperitoneal topotecanGlobal gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroidsA Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancerTopotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers.A phase I study to characterize the safety, tolerability, and pharmacokinetics of topotecan at 4 mg/m2 administered weekly as a 30-minute intravenous infusion in patients with cancer.Treatment for recurrent ovarian cancer-at first relapse.Initial testing of topotecan by the pediatric preclinical testing program.Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitorsDetermination of cancer antigen 125 in ovarian carcinoma.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Ex vivo analysis of topotecan: advancing the application of laboratory-based clinical therapeuticsMultipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.Topotecan: a new topoisomerase I inhibiting antineoplastic agent.Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5.Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
P2860
Q24644151-FE0F276E-B1DF-4191-8085-BE89CFAC6F79Q28366214-70F60269-6BFA-46D3-BF39-218CB1BFAAADQ33321330-F96EAA41-B07F-443B-B7CA-299668B56D1AQ33339062-FBBD84AE-DB59-4C59-9FD0-D5F011CFE214Q33366785-4C688CF0-47BF-4108-BA41-60251B7B4B04Q33379265-9E26DBF8-447B-4704-9681-8BC4F1B6EAF8Q33386523-1A6FB0EB-800E-4371-B43F-0D5EC205D69DQ33570711-88C2F0E0-D851-42DE-9883-D904A2BC1F12Q34073784-780C6DDE-2A0C-45AA-BABC-788F4F7FEC56Q34616645-B571DECB-7B8F-4226-B40E-CB8DC496821AQ36114881-2A0D915C-DFB9-4593-BFAB-5E2878335595Q36264942-8F0BF3E0-66DA-4611-95CE-024A89E85A82Q36488198-5AAEA3DF-8B70-46CB-BE68-780FC702C82EQ36671493-8961953A-1C71-40AA-ABA6-C9D87866988CQ38871242-798EC59C-CD6E-4C78-AD3A-962FF3BA51D9Q40708490-2706FF99-D3F3-447B-A82D-39007891908BQ42689189-4CE2067A-D983-443E-8B87-9CF9CFCD9331Q42862031-23264F93-EF24-402A-BD4E-17BB766FCBB1Q43992111-24B892A1-1051-4A8D-8020-5AE33467FEAFQ44168595-5A4CDB25-1A12-4726-919C-852D9C3CFBC3Q46963348-62D8D8B9-F6DE-4010-ADE5-BC9182F57A5E
P2860
Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Phase II study of intravenous ...... epithelial ovarian carcinoma.
@en
type
label
Phase II study of intravenous ...... epithelial ovarian carcinoma.
@en
prefLabel
Phase II study of intravenous ...... epithelial ovarian carcinoma.
@en
P2093
P1476
Phase II study of intravenous ...... epithelial ovarian carcinoma.
@en
P2093
A P Kudelka
C Gonzalez de Leon
C L Edwards
C Levenback
C Verschraegen
D Tresukosol
J J Kavanagh
P304
P356
10.1200/JCO.1996.14.5.1552
P407
P577
1996-05-01T00:00:00Z